内皮细胞活化增强疫苗诱导免疫性血栓性血小板减少症中的血栓炎症
疫苗诱导免疫性血栓性血小板减少症(VITT)是ChAdOx1 nCOV-19疫苗的罕见严重并发症。研究用包被内皮细胞的微流控装置Endo-chip检测临床VITT患者血清和IgG对内皮血栓炎症的影响,队列含40例VITT患者(21例ELISA阳性、19例ELISA阴性)、12例无VITT的疫苗接种后静脉血栓栓塞患者和17例无不良事件的疫苗接种者。VITT血清、血浆或IgG增加内皮组织因子表达和活性,灌注后血小板、中性粒细胞和纤维蛋白沉积增加两至三倍,加入PF4增强、抗TF抑制性抗体减弱血栓炎症。
要点
- VITT血清、血浆或IgG可增加内皮组织因子表达和活性
- Endo-chip灌注后血小板、中性粒细胞和纤维蛋白沉积增加两至三倍
- 加入PF4增强血栓炎症,抗TF抑制性抗体可减弱血栓炎症
核心结论
- 内皮活化参与临床VITT患者的血栓炎症。
- Endo-chip为免疫性血栓中内皮反应研究提供平台。
研究设计与样本
- 使用包被内皮细胞的微流控装置Endo-chip,检测临床VITT患者血清和IgG对内皮血栓炎症的影响。
- 队列含40例临床VITT患者(21例PF4/聚阴离子ELISA阳性、19例ELISA阴性)、12例疫苗接种后静脉血栓栓塞无VITT患者和17例接种ChAdOx1疫苗无不良事件者(疫苗对照)。
主要发现
- VITT血清、血浆或IgG处理增加内皮组织因子表达和活性。
- 健康供者血标记血小板、中性粒细胞和纤维蛋白抗体后灌注经VITT血清或IgG处理的Endo-chip,血小板、中性粒细胞和纤维蛋白沉积增加两至三倍。
- 加入PF4增强血栓炎症,加入抗TF抑制性抗体减弱血栓炎症。
- 符合VITT临床标准者中半数用PF4/聚阴离子ELISA检测阳性,另三分之一用血小板活化试验阳性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出VITT诊断所用检测方法存在局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious complication of the ChAdOx1 nCOV-19 vaccine. In Australia, the diagnosis of VITT required the detection of antibodies against platelet factor 4 (PF4) in plasma using a PF4/polyanion enzyme-linked immunosorbent assay (ELISA). Half of the patients who fulfilled the clinical criteria for VITT tested positive when using this ELISA and another third tested positive when using platelet activation assays, highlighting limitations in the assays used for VITT. Using a microfluidic device coated with endothelial cells, the Endo-chip, we measured the effects of serum and immunoglobulin G (IgG) from patients with clinical VITT on endothelial thromboinflammation. Our cohort comprised 40 patients (21 ELISA-positive and 19 ELISA-negative patients as measured by PF4/polyanion ELISA), 12 vaccinated patients with venous thromboembolism without VITT, and 17 individuals who received the ChAdOx1 vaccine without adverse events (vax controls). Treatment with VITT serum, plasma, or IgG increased endothelial tissue factor (TF) expression and activity. Perfusion of blood from healthy donors labelled with fluorescent antibodies against platelets, neutrophils, and fibrin through Endo-chips treated with VITT serum or IgG induced a twofold to threefold increase in platelet, neutrophil, and fibrin deposition. Thromboinflammation was enhanced with addition of PF4 and reduced with an inhibitory antibody against TF. We conclude that endothelial activation contributes to thromboinflammation in patients with clinical features of VITT. The Endo-chip offers a platform for the study of endothelial responses in immune thrombosis.
引用
- Dupuy A, Liu X, Kong Y, et al. Endothelial cell activation enhances thromboinflammation in vaccine-induced immune thrombotic thrombocytopenia. Blood Adv. 2025. PMID: 40085945. doi:10.1182/bloodadvances.2024014165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。